P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL

por Amatangelo, M., Cheng, Y., Pierceall, W., van de Donk, N. W., Lonial, S., Wang, M., Emerson, J., Hong, K., Maciag, P., Peluso, T., Gandhi, A., Thakurta, A.
Publicado 2022

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS

por Wester, R., van Duin, M., Lam, K.H., Couto, S.S., Ren, Y., Wang, M., Cupedo, T., van der Holt, B., Beverloo, H.B., Nigg, A.L., Thakurta, A., Waage, A.A., Zweegman, S., Broijl, A., Sonneveld, P.
Publicado 2023

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

por Thakurta, A, Gandhi, A K, Waldman, M F, Bjorklund, C, Ning, Y, Mendy, D, Schafer, P, Lopez-Girona, A, Lentzsch, S, Schey, S A, Calle, Y, Chelliah, R, Orlowski, R Z, Madan, A, Avet-Loiseau, H, Chopra, R
Publicado 2014

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF...

por Bjorklund, C C, Lu, L, Kang, J, Hagner, P R, Havens, C G, Amatangelo, M, Wang, M, Ren, Y, Couto, S, Breider, M, Ning, Y, Gandhi, A K, Daniel, T O, Chopra, R, Klippel, A, Thakurta, A G
Publicado 2015